Editors/Authors   Librarians   Newsletter   Site Tour   Subscriptions   A-Z Index   About   Contact Us   Help 
Log In | Log In via Athens
 
Disable Autosuggest
Care at the Close of Life: Evidence and Experience
Stephen J. McPhee, Margaret A. Winker, Michael W. Rabow, Steven Z. Pantilat, Amy J. Markowitz
Part B Symptom Management
Chapter 7. Management of Intractable Nausea and Vomiting in Patients at the End of Life: “I Was Feeling Nauseous All of the Time…Nothing Was Working”
Gordon J. Wood, MD, Joseph W. Shega, MD, Beth Lynch, NP, Jamie H. Von Roenn, MD
Table 7-2 Common Clinical Scenarios Associated With Nausea and Vomiting at the End of Life


Topics Discussed: 5-ht3 receptor antagonist, antiemetic agent, autonomic dysfunction, chemotherapy sickness, chlorpromazine, drug interactions, drug-induced nausea and vomiting, haloperidol, intestinal obstruction, motion sickness, nausea and vomiting, opioid-related disorder, palliative care, polypharmacy, practice guidelines, summarizing the evidence

Excerpt: "Thoughtful evaluation to determine both the cause of the symptoms and the pathophysiologic mechanism by which they are triggered allows directed therapy to begin. Therapy should include not only antiemetics but also measures to alleviate the cause of the symptoms, such as the proton pump inhibitor for Mr Q.Nonpharmacologic therapy is an important first consideration in the management of intractable nausea. Simple recommendations such as avoiding strong smells or other nausea triggers, eating small, frequent meals, and limiting oral intake during periods of extreme emesis are helpful.37,38 Psychological techniques, especially those that promote relaxation, can be helpful.39,40 Acupuncture and acupressure may provide some benefit in the setting of chemotherapy or surgery. A systematic review found benefit to P6 stimulation (just above the wrist) in 11 of 12 randomized, placebo-controlled trials.41 Emerging evidence from randomized trials suggests that acupressure wrist bands may also be effective.42,43 Medical devices, including gastric electrical stimulation44 and transcutaneous electrical nerve stimulation units,45 are currently under investigation, but a lack of convincing evidence and substantial cost currently limit their use...."
Log in to read the full chapter:
Subscriber Log In
Username:
Password:
Forgot your username/password?
Or  
Get full access to JAMAevidence two ways:
Subscribe to JAMAevidence
JAMAevidence is a subscription-
based website dedicated to the learning, teaching, and practicing of evidence-based medicine.
Pay Per View
Timed access to all of JAMAevidence
24 hours for $29.95
48 hours for $49.95
Copyright © American Medical Association. All rights reserved.  |  JAMA  |  The McGraw-Hill Companies, Inc.
Privacy Notice. Any use is subject to the Terms of Use and Notice. Additional Credits and Copyright Information.
Your IP address is 38.107.179.241